This week’s episode features Paul Glue, professor of Psychiatry at the Dunedin School of Medicine, University of Otago, New Zealand.
With a vast experience in both academia and pharmaceutical industry, Paul Glue’s research focuses on clinical and basic science to investigate the pharmacology of drug treatments in psychiatry and the disease mechanisms of neurological and psychiatric disorders. He is also interested in psychopharmacology and the development of novel therapeutics for affective disorders. One of these novel substances that have dominated his career is ketamine for treatment-resistant depression. Professor Glue hopes that his development of oral ketamine (rather than intravenous) will bring ketamine treatment from the clinics “back to people’s bathrooms”.
Tune in to this episode to listen to a fascinating conversation between two great scientists about, well… Drug Science.
National Institute on Alcohol Abuse and Alcoholism
Electroconvulsive therapy (ECT)
Overexcitement and disinhibition
Dynamic Neurotransmitter Interactions in Alcohol Withdrawal by Paul Glue and David Nutt
Treatment-resistant depression
Ketamine Assisted Psychotherapy
Montgomery-Asberg Depression Rating Scale
Mechanisms of ketamine action as an antidepressant – P Zanos, T D Gould
Food and Drug Administration (FDA)
Medicines and Healthcare products Regulatory Agency
Good manufacturing practice (GMP)
The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation
Psychedelics Promote Structural and Functional Neural Plasticity – Ly et al.